Table 2.
MRI activity at baseline (2nd-line treatment initiation), 12 and 24 months, according treatment group
| Variable | FIN (n = 49) | NTZ (n = 46) | p value |
|---|---|---|---|
| No. of T1 gadolinium-enhancing lesions, mean ± SD | |||
| At baseline | 1.18±3.17 | 1.48±2.35 | 0.3492 |
| At 12 months | 0.27±0.64 | 0.02±0.15 | 0.0103 |
| At 24 months1 | 0.10±0.31 | 0.14±0.49 | 0.9037 |
| Patients free of T1 gadolinium-enhancing lesions, % | |||
| At baseline | 56.1 | 50.0 | 0.7654 |
| At 12 months | 81.6 | 97.8 | 0.0159 |
| At 24 months1 | 90.0 | 91.7 | 1.0000 |
| Patients free of new or increased T2 lesions2, % | |||
| At 12 months | 75.5 | 100 | 0.0003 |
| At 24 months1 | 85.0 | 97.2 | 0.1249 |
| Change in the number of T1 gadolinium-enhancing lesions at 12 months2, mean ± SD | −0.92±3.25 | −1.46±2.35 | 0.0512 |
| Percent change in the number of T1 gadolinium-enhancing lesions at 12 months2, 3 (95% CI) | −64.3 (−100.2 to −28.5) | −95.6 (−104.7 to −86.6) | 0.0809 |
1
For these variables, no. of evaluable patients = 20 for FIN group and n = 36 for NTZ group.
2
Compared to baseline.
3
For this variable, no. of evaluable patients = 23 in both groups.
FIN, fingolimod; NTZ, natalizumab.